The STARS (STeroids Against Re-Stenosis) Trial[THE USE OF Peri-PROCEDURAL ORAL CORTICOSTERIODS TO PREVENT IN-SEGMENT RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION.] - The STARS Trial

South Tees Hospitals NHS Foundation Trust0 个研究点目标入组 548 人开始时间: 2005年5月27日最近更新: 2020年7月27日

试验速览

暂无简介。

•Any patient awaiting percutaneous coronary intervention for symptomatic coronary artery disease (elective or acute).
•Documented myocardial ischaemia.
•Coronary angiography demonstrating at least a 50% reduction of the luminal diameter in at least one native coronary artery (as measured by quantitative computerised angiography).
•Ammendment: Any lesion for which the operator (interventional consultant cardiologist) feels a non-drug eluting stent is appropriate
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Left Main Stem stenosis
•PCI for ST elevation myocardial infarction
•Steroid therapy within 30-days of study enrolment.
•Contraindication to corticosteroid use.
•Previous inclusion in this study.
•Non-cardiac disease likely to cause death within 6-months.
•(Proposed use of a drug eluting stent.) Ammendment: Proposed use of a drug eluting stent (in the study lesion(s)).
•Inter-hospital transfers from Cumbria.

发起方